BMO Capital analyst Matt Borsch raised his price target on UnitedHealth to $300 after its meeting with investors and a positive update on its current state of the business. The analyst contends that the company's advantage over competitors is stronger than it has ever been before as it widens its lead "in terms of product, innovation, technology, scope, and scale". Borsch keeps his Outperform rating on UnitedHealth, adding that the company could further benefit from competitors' distractions such as the pending CVS (CVS) - Aetna (AET) and Cigna (CI) -Express Scripts (ESRX) mergers.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here